At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
Exenatide +3 moredrug
Likely dose
Exenatide 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exenatide Once Weekly for Smoking Cessation: A Randomized Clinical Trial
The University of Texas Health Science Center, Houston·interventional·Posted Nov 29, 2016·Updated Jan 28, 2021
In Brief
A Phase 2 clinical trial evaluating Exenatide, NRT, and 2 other interventions for Smoking Cessation. Completed, enrolled 84 participants across 1 site.
Detailed Summary
The purpose of this study is to identify a potential new treatment for smoking cessation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJul 2016
First PostedNov 2016
Primary CompletionJan 2020
TodayJul 2026
First PostedNov 29, 2016
Enrollment StartJul 1, 2016
Primary CompletionJan 3, 2020
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 9.6 years ago
Interventions
Exenatidedrug
Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.
NRTdrug
Nicotine Patch (21mg) / 24 hours.
Counselingbehavioral
Brief individual behavioral smoking cessation counseling.
Placebodrug
Normal saline.